1 / 34

Transporters: Focus on OATP1B1 and Selected Renal Transporters Kathy Giacomini University of California, San Francisco

Transporters: Focus on OATP1B1 and Selected Renal Transporters Kathy Giacomini University of California, San Francisco. Selected Membrane Transporters in Human Genome. ENT1 ENT2. MATE1-2. MRP1-4. CNT1 CNT2 CNT3. Organic Cations. Nucleosides. Hydrophobic Anions. Nucleosides. MDR1

anemone
Download Presentation

Transporters: Focus on OATP1B1 and Selected Renal Transporters Kathy Giacomini University of California, San Francisco

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Transporters: Focus on OATP1B1 and Selected Renal Transporters Kathy Giacomini University of California, San Francisco

  2. Selected Membrane Transporters in Human Genome ENT1 ENT2 MATE1-2 MRP1-4 CNT1 CNT2 CNT3 Organic Cations Nucleosides Hydrophobic Anions Nucleosides MDR1 MDR3 BSEP OCTs OCTNs OATs Organic Ions Hydrophobic Cations VMAT VAChT Neurotransmitters Fe+++ Organic Anions DAT NET GAT1 SERT Oligopeptides NRAMP1 DMT1 IREG1 OATPs PEPT1 PEPT2 ABC Family ~ 50 SLC Family ~ 300

  3. Transporters in the Liver Blood MRP1,3 BCRP OCT1 MDR1,3 OAT2 Bile MRP2 OATP 1B1, 1B3 2B1 BSEP NTCP Hepatocyte

  4. Is OATP1B1 Important for Drug-Drug Interactions? • What is the evidence? • In vitro evidence • In vivo evidence

  5. Selected Substrates of OATPs OATP1B1:benzylpenicillin, atorvastatin,cerivastatin, fluvastatin, pitavastatin, pravastatin, rosuvastatin, methotrexate, nateglinide, repaglinide, rifampin OATP1B3:digoxin, fexofenadine, fluvastatin, pravastatin,methotrexate, paclitaxel, rifampin OATP2B1:benzylpenicillin, fexofenadine, fluvastatin, pravastatin OATP 1B1 OATP 1B3 OATP 2B1

  6. Is OATP1B1 Important for Drug-Drug Interactions? • What is the evidence? • In vitro evidence • In vivo evidence

  7. In Vivo Evidence • Genetic Studies • Knockout/transgenic Mice • Polymorphisms in Humans • Chemical Inhibition Studies

  8. In Vivo Evidence • Genetic Studies • Knockout Mice: Not applicable • Polymorphisms in Humans • Chemical Inhibition Studies:Specific inhibitors • not available

  9. Individuals with Polymorphisms of OATP1B1 Have Higher Plasma Levels of Repaglinide Homozygous 521CC Homozygous 521TT Niemi M. et al, Clin Pharmacol Ther 2005; 77:468-78

  10. Individuals with Polymorphisms of ABCB1 Have Similar Plasma Levels of Repaglinide Niemi M. et al, Clin Pharmacol Ther 2005; 77:468-78

  11. Individuals with Polymorphisms of CYP3A5 Have Similar Plasma Levels of Repaglinide Niemi M. et al, Clin Pharmacol Ther 2005; 77:468-78

  12. Individuals with Polymorphisms of OATP1B1 Have Higher Plasma Levels of Fexofenadine Homozygous 521CC Homozygous 521TT Niemi M. et al, British Journal of Clinical Pharmacology 2005, 59: 602-604

  13. Individuals with Polymorphisms of OATP1B1 Have Higher Plasma Levels of Pravastatin 11187GA 11187GG Niemi M. et al, Pharmacogenetics. 2004 Jul;14(7):429-40.

  14. Individuals with Polymorphisms of OATP1B1 Have Higher Plasma Levels of Pravastatin 521CC 521TC 521TT Niemi M. et al, Pharmacogenetics. 2004 Jul;14(7):429-40.

  15. Individuals with Polymorphisms of OATP1B1 Have Higher Plasma Levels of Pravastatin *17 Heterozygotes Niemi M. et al, Pharmacogenetics. 2004 Jul;14(7):429-40.

  16. OATP1B1 Genetic Studies:Compelling Evidence that OATP1B1 Plays a Role in Drug Disposition Chemical Inhibition Studies:Specific inhibitors not available

  17. +itraconazole+gemfibrozil +gemfibrozil +itraconazole Drug-Drug Interactions with Repaglinide Itraconazole: CYP3A4 inhibitor P-gp inhibitor Gemfibrozil: CYP2C8 and OATP1B1 inhibitor Niemi M. et al, Diabetologia. 2003 Mar;46(3):347-51.

  18. Increase in Plasma Levels of Repaglinide by Trimethoprim, A CYP2C8 Inhibitor +trimethoprim Trimethoprim: CYP2C8 inhibitor Niemi M. et al, Br J Clin Pharmacol. 2004 Apr;57(4):441-7

  19. OATP1B1 Genetic Studies:Compelling evidence that OATP1B1 plays a role in drug disposition Chemical Inhibition Studies:Inhibitor studies are suggestive, but not definitive.

  20. Recommendations to Consider • Perform in vitro studies in cells expressing OATP1B1- Assess if NME is substrate/inhibitor • If in vitro data show evidence of interaction • with OATP1B1 • Substrate: Possibly perform clinical Interaction study with gemfibrozil or rifampicin as inhibitor of NME • Inhibitor: Possibly perform clinical Interaction study • with NME as inhibitor of fexofenadine (no metabolism) • or atorvastatin/pravastatin

  21. Selected Membrane Transporters in Human Genome ENT1 ENT2 MATE1-2 MRP1-4 CNT1 CNT2 CNT3 Organic Cations Nucleosides Hydrophobic Anions Nucleosides MDR1 MDR3 BSEP OCTs OATs Organic Ions Hydrophobic Cations VMAT VAChT Neurotransmitters Fe+++ Organic Anions DAT NET GAT1 SERT Oligopeptides NRAMP1 DMT1 IREG1 OATPs PEPT1 PEPT2 ABC Family ~ 50 SLC Family ~ 300

  22. MATE -1 OCTN1/2 hOCT2/3 hOAT1/3 Renal Drug Transporters Urine Blood Li M et al. Expert Opin Drug Metab Toxicol 2006

  23. Organic Cation Transporters (OCTs/OCTNs) OCT2 Organic Anion Transporters (OATs) OAT1 OAT3 Expression of Various Renal Transporters in Human Kidney

  24. OCT2, OAT1 and OAT3: Important for Drug-Drug Interactions? • What is the evidence? • In vitro evidence • In vivo evidence

  25. OCTN1 OCTN2 Selected Substrates of OATs and OCTs OAT1: acyclovir, adefovir, cidofovir, methotrexate OAT3:estrone sulfate, methotrexate, cimetidine, tetracycline OCT2:amantadine, memantine, cimetidine, metformin OAT1 OAT3 OCT2

  26. In Vivo Evidence • Genetic Studies • Knockout/transgenic Mice: Available • Polymorphisms in Humans • Chemical Inhibition Studies: Selective • but not specific inhibitors are available

  27. Knockout Mouse Models • Oat1-/- Mice • Decreased CLR of para-aminohippurate, furosemide, endogenous organic anions (Eraly et al. J Biol Chem 2006) • Oat3-/- Mice • Reduced uptake of para-aminohippurate, estrone sulfate in kidney slices and choroid plexus (Sweet et al. J Biol Chem 2002 ; Sykes et al. AJP Ren Physiol 2004) • Oct1/2-/- Mice • Complete loss of active secretion of tetraethylammonium (Jonker et al. Mol Cell Biol 2003)

  28. p = 0.045 Preliminary Data on Cefotaxime and GeneticVariants of OAT3: Unpublished Data

  29. p = 0.045 Preliminary Data on Gabapentin and GeneticVariants of OCTN1: Unpublished Data Cells Clinical

  30. p = 0.007 Preliminary Data on Gabapentin and GeneticVariants of OCTN1: Unpublished Data Cells Clinical

  31. In Vivo Evidence • Genetic Studies • Knockout/transgenic Mice: Available • Polymorphisms in Humans • Chemical Inhibition Studies: Selective • but not specific inhibitors are available

  32. Drug-Drug Interactions Related to Renal Drug Transporters • Organic Anion Transporters (OATs): • Cefazolin/Probenecid (~38% ↓ cefazolin CLR) (Spina et al. Ann Pharmacother 2003, Sakurai et al. Pharm Res 2004) • Organic Cation Transporters (OCTs): • Procainamide/Cimetidine (42% ↓ procainamide CLR) (Somogyi et al. Eur J Clin Pharmacol 1983) • Metformin/Cimetidine (28% ↓ metformin CLR) (Somogyi et al. Br J Clin Pharmacol 1987)

  33. Other DDIs Potentially Resulting From Renal Transporter Interactions • Methotrexate/NSAIDs • Furosemide/Probenecid • Pindolol/Cimetidine • Amiloride/Cimetidine • Procainamide/Trimethoprim Charge Specific Inhibitors

  34. Recommendations to Consider • Perform in vitro studies in cells expressing OAT1, OAT3 or OCT2- Assess if NME is substrate/inhibitor • If in vitro data show evidence of interaction with OCT2, OAT1 or OAT3 • Substrate of OCT2: Cimetidine inhibition • Inhibitor of OCT2: Metformin • Substrate of OATs: Probenecid • Inhibitor of OATs: Cefazolin

More Related